Arcus Biosciences, Inc. income statement

In fiscal 2025, Arcus Biosciences, Inc. reported revenue of $247m, down 4.3% on the year before, operating income of −$386m (a -156.3% margin) and net income of −$353m, or −$3.29 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Arcus Biosciences, Inc.: income statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	1	8	15	78	383	112	117	258	247	117
Research and development	47	50	78	159	257	288	340	448	523	497
General and administrative	8	14	25	43	72	104	117	120	110	106
Operating income	−53	−55	−89	−124	54	−280	−340	−330	−386	−486
Interest expense	—	—	—	—	—	2	2	4	8	11
Provision for credit losses	—	—	0	0	0	0	0	0	0	0
Income before tax	—	—	−85	−123	55	−266	−301	−282	−353	−460
Income tax	—	—	—	—	2	1	6	1	0	0
Net income	−53	−50	−85	−123	53	−267	−307	−283	−353	−460
Diluted EPS	−$1.45	−$1.43	−$1.93	−$2.24	$0.71	−$3.71	−$4.15	−$3.14	−$3.29	−$3.86
Diluted shares (average)	37m	35m	44m	55m	74m	72m	74m	90m	107m	119m
EBITDA	−51	−51	−85	−121	58	−274	−332	−320	−376	−476

US$ millions unless shown otherwise. Fiscal quarters.

Arcus Biosciences, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	48	26	28	160	26	33	17	41
Research and development	123	101	122	139	141	121	122	113
General and administrative	30	28	28	29	27	26	29	24
Operating income	−105	−103	−122	−8	−142	−114	−134	−96
Interest expense	1	2	1	2	3	2	3	3
Provision for credit losses	0	0	0	0	0	0	0	0
Income before tax	−92	−93	−112	0	−135	−106	−128	−91
Income tax	0	1	0	0	0	0	0	0
Net income	−92	−94	−112	0	−135	−106	−128	−91
Diluted EPS	−$1.00	−$1.03	−$1.14	$0.00	−$1.27	−$0.90	−$1.02	−$0.72
EBITDA	−103	−100	−119	−6	−140	−111	−132	−93

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: RCUS vs SPRY MESO vs RCUS RCUS vs XNCR AGEN vs RCUS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcus Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcus Biosciences, Inc.